36
Maintenance
FOLFIRI
Bevacizumab +
fluoropyrimidin
e
Treatment of mCRC: ESMO recommendations
*Cetuximab and Panitumumab are approved in RAS wt mCRC patients only
†
In 2L, switch CT from oxaliplatin- to irinotecan-based, or vice versa, from CT
used in 1L
CT-only treatment may be considered in all lines
CT, chemotherapy
Van Cutsem E et al. Ann Oncol. 2016;27:1386-422.
1L
Panitumumab*
±
CT doublet
Bevacizumab +
CT triplet,
doublet or
monotherapy
Cetuximab* ±
CT doublet
2L
Ziv-aflibercept
+ CT
†
doublet
Ramucirumab
+ CT
†
doublet
Panitumumab*
± CT
†
doublet
or
monotherapy
Bevacizumab +
CT
†
doublet or
monotherapy
Cetuximab* ±
CT
†
doublet or
monotherapy
3L
LONSURF
Panitumumab*
± CT doublet
or
monotherapy
Cetuximab* ±
CT doublet or
monotherapy
Regorafenib
